|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | |||||||||||||||
| CURRENT ASSETS | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Inventory | |||||||||||||||
| Prepaid expenses - related party | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Nonrelated Party | |||||||||||||||
| Related Party | |||||||||||||||
| Total prepaid expenses | |||||||||||||||
| Deposits | |||||||||||||||
| Related Party | |||||||||||||||
| Total deposits | |||||||||||||||
| Digital assets – USDT held by agent | |||||||||||||||
| Due from related party | |||||||||||||||
| TOTAL CURRENT ASSETS | |||||||||||||||
| NON-CURRENT ASSETS | |||||||||||||||
| Property and equipment, net of accumulated depreciation of $3,770 and $3,268 | |||||||||||||||
| Right of use - asset | |||||||||||||||
| Intangible assets - acquired patents and license, net of amortization | |||||||||||||||
| Deposits | |||||||||||||||
| TOTAL OTHER ASSETS | |||||||||||||||
| TOTAL NON-CURRENT ASSETS | |||||||||||||||
| TOTAL ASSETS | |||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||
| CURRENT LIABILITIES | |||||||||||||||
| Accounts payable and accrued liabilities | |||||||||||||||
| Nonrelated Party | |||||||||||||||
| Related Party | |||||||||||||||
| Total accounts payable and accrued liabilities | |||||||||||||||
| Payroll tax liabilities | |||||||||||||||
| Deposit/contract liability | |||||||||||||||
| Operating lease liability - current | |||||||||||||||
| Accrued liabilities - related parties | |||||||||||||||
| Notes payable | |||||||||||||||
| Nonrelated Party | |||||||||||||||
| Related Party | |||||||||||||||
| Total notes payable | |||||||||||||||
| Other liabilities | |||||||||||||||
| Related Party | |||||||||||||||
| Patent Purchase Payable | |||||||||||||||
| Total other liabilities | |||||||||||||||
| TOTAL CURRENT LIABILITIES | |||||||||||||||
| LONG-TERM LIABILITIES | |||||||||||||||
| Operating lease liability - net of current portion | |||||||||||||||
| TOTAL LONG-TERM LIABILITIES | |||||||||||||||
| TOTAL LIABILITIES | |||||||||||||||
| STOCKHOLDERS’ EQUITY | |||||||||||||||
| Preferred stock, value | |||||||||||||||
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 21,567,420 and 15,888,795 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||||||
| Stock warrants | |||||||||||||||
| Subscription receivable | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||
| TOTAL MANGOCEUTICALS, INC. STOCKHOLDERS’ EQUITY | |||||||||||||||
| Non-controlling interest | |||||||||||||||
| TOTAL EQUITY | |||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||
Loading...